NCT01800006 - Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region | Biotech Hunter

Enrollment

2,101

Participants

Timeline

Start Date

January 14, 2013

Primary Completion Date

January 16, 2016

Study Completion Date

June 20, 2016

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.

Trial Locations (17)

Unknown

Many Locations

ManyLocations

Many Locations

ManyLocations

Many Locations

ManyLocations

Many Locations